Key Points
- CFO Michael Brian Bell sold 3,000 Guardant Health shares on March 16 at an average price of $87.04 for a total of $261,120, leaving him with 43,601 shares (a 6.44% reduction in his position).
- Guardant Health reported quarterly EPS of ($0.50), missing estimates by $0.07, while revenue was $281.27 million—beating forecasts and rising 39.4% year-over-year.
- Analyst sentiment is largely positive with 21 Buy ratings and a consensus target of $122.57, and several firms have recently raised price targets into the $130–150 range despite one firm reissuing a Sell.
Guardant Health, Inc. (NASDAQ:GH - Get Free Report) CFO Michael Brian Bell sold 3,000 shares of the stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $87.04, for a total transaction of $261,120.00. Following the transaction, the chief financial officer directly owned 43,601 shares of the company's stock, valued at $3,795,031.04. The trade was a 6.44% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
Guardant Health Stock Performance
Guardant Health stock opened at $88.75 on Wednesday. The company has a market capitalization of $11.64 billion, a PE ratio of -26.81 and a beta of 1.67. Guardant Health, Inc. has a fifty-two week low of $36.36 and a fifty-two week high of $120.74. The firm has a 50 day moving average price of $103.15 and a 200 day moving average price of $90.33.
Guardant Health (NASDAQ:GH - Get Free Report) last issued its quarterly earnings results on Thursday, February 19th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.07). The firm had revenue of $281.27 million for the quarter, compared to analyst estimates of $269.74 million. During the same quarter in the previous year, the company earned ($0.62) earnings per share. The business's quarterly revenue was up 39.4% on a year-over-year basis. As a group, equities research analysts forecast that Guardant Health, Inc. will post -2.9 earnings per share for the current year.
Analyst Upgrades and Downgrades
Several equities analysts have commented on GH shares. Citigroup raised their price target on shares of Guardant Health from $135.00 to $150.00 and gave the company a "buy" rating in a research report on Friday, February 20th. Guggenheim upped their price objective on Guardant Health from $115.00 to $135.00 and gave the stock a "buy" rating in a research report on Monday, January 26th. Stifel Nicolaus increased their price objective on Guardant Health from $120.00 to $130.00 and gave the company a "buy" rating in a research note on Friday, February 20th. TD Cowen lifted their target price on Guardant Health from $130.00 to $135.00 and gave the company a "buy" rating in a report on Friday, February 20th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Guardant Health in a research note on Thursday, January 22nd. Twenty-one equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, Guardant Health presently has an average rating of "Moderate Buy" and a consensus target price of $122.57.
Get Our Latest Stock Report on Guardant Health
Institutional Inflows and Outflows
A number of institutional investors have recently added to or reduced their stakes in the company. AQR Capital Management LLC increased its position in shares of Guardant Health by 56.5% in the 1st quarter. AQR Capital Management LLC now owns 71,534 shares of the company's stock valued at $3,012,000 after purchasing an additional 25,831 shares during the last quarter. Empowered Funds LLC purchased a new stake in shares of Guardant Health during the 1st quarter worth $274,000. Envestnet Asset Management Inc. grew its stake in shares of Guardant Health by 40.5% during the second quarter. Envestnet Asset Management Inc. now owns 38,622 shares of the company's stock worth $2,010,000 after purchasing an additional 11,125 shares in the last quarter. Prospera Financial Services Inc acquired a new position in shares of Guardant Health during the second quarter worth $236,000. Finally, Allworth Financial LP increased its holdings in Guardant Health by 358.4% in the second quarter. Allworth Financial LP now owns 706 shares of the company's stock valued at $37,000 after buying an additional 552 shares during the last quarter. Hedge funds and other institutional investors own 92.60% of the company's stock.
About Guardant Health
(
Get Free Report)
Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health's mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.
The company's flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
